A detailed history of Simplex Trading, LLC transactions in Insmed Inc stock. As of the latest transaction made, Simplex Trading, LLC holds 59,561 shares of INSM stock, worth $4.4 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
59,561
Holding current value
$4.4 Million
% of portfolio
0.15%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$62.0 - $79.01 $3.69 Million - $4.71 Million
59,561 New
59,561 $4.35 Million
Q1 2024

Apr 25, 2024

BUY
$25.72 - $29.94 $540,300 - $628,949
21,007 New
21,007 $569,000
Q2 2023

Aug 04, 2023

BUY
$16.44 - $21.1 $378,185 - $485,384
23,004 Added 1769.54%
24,304 $512,000
Q1 2023

Apr 27, 2023

BUY
$16.26 - $21.73 $21,138 - $28,249
1,300 New
1,300 $22,000
Q3 2021

Oct 28, 2021

SELL
$22.46 - $29.47 $24,706 - $32,417
-1,100 Reduced 10.59%
9,284 $273,000
Q2 2021

Aug 12, 2021

BUY
$24.17 - $36.01 $89,356 - $133,128
3,697 Added 55.29%
10,384 $295,000
Q1 2021

Apr 26, 2021

BUY
$32.28 - $44.3 $174,989 - $240,150
5,421 Added 428.2%
6,687 $227,000
Q4 2020

Feb 02, 2021

SELL
$31.45 - $40.54 $865,472 - $1.12 Million
-27,519 Reduced 95.6%
1,266 $42,000
Q3 2020

Oct 14, 2020

BUY
$26.0 - $34.5 $748,410 - $993,082
28,785 New
28,785 $925,000
Q1 2020

Apr 29, 2020

SELL
$13.63 - $33.98 $100,303 - $250,058
-7,359 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$16.12 - $24.98 $118,627 - $183,827
7,359 New
7,359 $175,000
Q3 2019

Oct 15, 2019

SELL
$15.49 - $25.78 $15,815 - $26,321
-1,021 Closed
0 $0
Q2 2019

Jul 26, 2019

BUY
$23.0 - $32.19 $23,483 - $32,865
1,021 New
1,021 $26,000
Q1 2019

Apr 18, 2019

SELL
$13.91 - $31.15 $11,128 - $24,920
-800 Closed
0 $0
Q4 2018

Jan 16, 2019

BUY
$11.6 - $18.7 $9,280 - $14,960
800 New
800 $10,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.